摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-dichloro-5-(2-chloroethyl)-6-methylpyrimidine | 89793-69-1

中文名称
——
中文别名
——
英文名称
2,4-dichloro-5-(2-chloroethyl)-6-methylpyrimidine
英文别名
2,4-dichloro-5-(2-chloro-ethyl)-6-methyl-pyrimidine;5-(2-chloraethyl)-6-methyl-2,4-dichlorpyrimidin
2,4-dichloro-5-(2-chloroethyl)-6-methylpyrimidine化学式
CAS
89793-69-1
化学式
C7H7Cl3N2
mdl
MFCD25968551
分子量
225.505
InChiKey
ZEDIRTAHPSPMSW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    85 °C
  • 沸点:
    136 °C(Press: 4 Torr)
  • 密度:
    1.407±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.428
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS
    申请人:GRÜNENTHAL GMBH
    公开号:US20160152624A1
    公开(公告)日:2016-06-02
    Novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    本发明涉及一种通式(I)的新型替代的浓缩嘧啶化合物,其中化学基团、取代基和指数如描述中所定义,并且涉及其作为药物的用途,特别是作为治疗可以通过抑制PDE4酶来治疗的疾病和病症的药物。
  • 作为JAK激酶抑制剂的吡咯并[2,3-d]嘧啶类衍生物及制备方法和用途
    申请人:中国药科大学
    公开号:CN114292274A
    公开(公告)日:2022-04-08
    本发明公开了具有通式(I)的吡咯并[2,3‑d]嘧啶类衍生物或其可药用的盐作为JAK激酶抑制剂用于预防、治疗或改善包括例如炎性疾病和自身免疫疾病(例如,类风湿性关节炎、银屑病、炎性肠炎疾病、系统性红斑狼疮、牛皮癣、斯耶格伦氏综合征、白塞氏病、多发性硬化等等)以及癌症(例如,巨大淋巴结增生症、淋巴瘤、白血病多发性骨髓瘤或骨髓增生性疾病等等)等等的JAK相关性疾病的药物。本发明化合物具有优良的JAK激酶(Janus Kinase)抑制活性。本发明还提供包含所述化合物及其可药用的盐,药学上可接受的载体或辅料及其制备方法。
  • Synthesis, X-ray crystal structure study and antitumoral evaluations of 5,6-disubstituted pyrimidine derivatives
    作者:Tatjana Gazivoda Kraljević、Svjetlana Krištafor、Lidija Šuman、Marijeta Kralj、Simon M. Ametamey、Mario Cetina、Silvana Raić-Malić
    DOI:10.1016/j.bmc.2010.02.023
    日期:2010.4
    5,6-Disubstituted pyrimidine derivatives (3-20) were prepared by intramolecular cyclization reaction of alpha-(1-carbamyliminomethylene)-gamma-butyrolactone (2) with sodium ethoxide and subsequent chemical transformation of 2-hydroxy group in C-5 side chain as well as lithiation reaction for introduction of acyclic side chain at C-6. All compounds were characterized by H-1 NMR, C-13 NMR and mass spectra. Structures of compounds 4, 7 and 14 were unambiguously confirmed by X-ray crystal structural analysis. Supramolecular structures of these three compounds differ significantly. Two N-H center dot center dot center dot O and one C-H center dot center dot center dot O hydrogen bonds in 4 form three-dimensional network. One O-H center dot center dot center dot N hydrogen bond and one pi center dot center dot center dot pi interaction self-assemble the molecules of 7 into sheets. In supramolecular aggregation of 14, only pi center dot center dot center dot pi stacking interactions participate, so forming chains. The compounds were evaluated for their cytostatic activities against human malignant cell lines. Of all tested compounds, 2,4-dimethoxy-5-methoxy-tritylethylpyrimidine (9) and 2,4-dichloro-5-chloroethylpyrimidine (14) exhibited the most prominent inhibitory effects. Furthermore, compound 14 showed marked activity against human colon carcinoma (IC50 = 0.4 mu M). (C) 2010 Elsevier Ltd. All rights reserved.
  • EP3030565A1
    申请人:——
    公开号:EP3030565A1
    公开(公告)日:2016-06-15
  • US9688683B2
    申请人:——
    公开号:US9688683B2
    公开(公告)日:2017-06-27
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台